VBIV - Multiplikator Forward P/S VBI Vaccines Inc.

The collapse of the partner network and subsequent bankruptcy led to a sell-off of VBI Vaccines Inc. (VBIV) assets, triggering a sharp spike in the business's forward P/S ratio. Despite its authority in developing brain cancer vaccines and its pricing power derived from the efficacy of its hepatitis B drug, the metric reached 0.20, confirming the company's systemic degradation.
VBI Vaccines (VBIV) - rincian metrik lan laporan keuangan

Patent protection for the VLP platform developed by VBI Vaccines Inc. (VBIV) to combat brain cancer and hepatitis B establishes a foundation of resilience reflected in the dynamics of the expected P/S ratio. This indicator benchmarks market capitalization against projected revenue, allowing investors to assess the market's confidence in future sales and determine the balance between speculative undervaluation and the risk of capital loss amid volatile forecasts.